HLA-C and nonpapillary renal cell carcinoma: Next, the immunoinhibitors, immunostimulators, chemokines, lymphocytes, MHC molecules, and immune receptors that were significantly associated with A2M in the immunotherapy response of ccRCC patients were explored (Figure 6).